Pure Global

Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis - Trial NCT06278350

Access comprehensive clinical trial information for NCT06278350 through Pure Global AI's free database. This Phase 2 trial is sponsored by InventisBio Co., Ltd and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 160 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06278350
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06278350
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis

Study Focus

Plaque Psoriasis

D-2570

Interventional

drug

Sponsor & Location

InventisBio Co., Ltd

Beijing, China

Timeline & Enrollment

Phase 2

Feb 04, 2024

Mar 31, 2025

160 participants

Primary Outcome

Percentage of subjects with at least 75% improvement in PASI

Summary

This is a randomized, double-blind, placebo-controlled, multicenter clinical trial in
 participants with moderate-to-severe plaque psoriasis .

ICD-10 Classifications

Psoriasis
Large plaque parapsoriasis
Other psoriasis
Small plaque parapsoriasis
Arthropathic psoriasis

Data Source

ClinicalTrials.gov

NCT06278350

Non-Device Trial